Why the study?
Does perioperative chemotherapy improve outcomes in patients with localized soft tissue sarcoma?
Does perioperative chemotherapy improve outcomes in patients with localized soft tissue sarcoma?
Answers are grounded in this paper and cite their sources.
The use of perioperative chemotherapy in localized soft tissue sarcoma remains debated and is currently considered an option only for high-risk patients.
The debate concerning perioperative chemotherapy use in localized soft tissue sarcoma (STS) is mired in a dead-end, following the results of a dozen of randomized studies completed by two meta-analyses. In the current guidelines [1], chemotherapy is not yet considered as a standard of care and may be proposed as an option in high-risk patients, currently imperfectly identified with classical factors as tumor size, depth and (Fédération Française des Centres de Lutte Contre le Cancer) FNCLCC grade [2].
No takes yet. Share an insight, caveat, or question.
Valentin et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: